Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the OVERCOME trial.

@article{Bosch2011PreventionOC,
  title={Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the OVERCOME trial.},
  author={Xavier Bosch and Jordi Esteve and Marta Sitges and Teresa Mar{\'i}a de Caralt and Ariadna Dom{\`e}nech and Jos{\'e} Tom{\'a}s Ortiz and M Monzo and Manuel Morales-Ruiz and Rosario Jes{\'u}s Perea and Montserrat Comas Rovira},
  journal={Journal of cardiac failure},
  year={2011},
  volume={17 8},
  pages={643-8}
}
BACKGROUND The current treatment of hematologic malignancies includes diverse potentially cardiotoxic chemotherapy agents, including high-dose myeloablative regimens used in autologous hematopoietic stem cell transplantation (HSCT). Many of these treatments could induce left ventricular dysfunction (LVD), and limit their efficacy. Angiotensin-converting enzime inhibitors and beta-blockers prevent LVD and prolong survival after infarction, and recent animal and pilot clinical studies suggest… CONTINUE READING